Antibody-Based Therapeutics and Diagnostics in Precision Genomic Medicine

A special issue of GenoMed Connect (ISSN 3006-9033).

Special Issue Editors

Dr. Yuanzhi Chen Lead Guest Editor School of Public Health, Xiamen University, Xiamen, China

Dr. Lijie Yuan Co-Guest Editor Organiod platform of medical laboratory science, Key laboratory of functional and clinical translational medicine, Fujian province university, Xiamen Medical College, Xiamen, China

Overview and Rationale

This Special Issue aims to highlight recent advances and future directions in the development and application of antibody-based technologies in precision medicine, translational genomics, and clinical practice. Antibodies—including monoclonal antibodies, bispecific antibodies, nanobodies, and antibody-drug conjugates (ADCs)—are increasingly being integrated into genomic medicine workflows to enable disease-specific diagnosis, targeted therapy, and molecular imaging.

We invite contributions from multidisciplinary teams that explore how antibody engineering, sequencing-based discovery platforms, and genomic data can be jointly leveraged to accelerate the development of personalized interventions in cancer, infectious diseases, rare genetic disorders, autoimmune diseases, and more.

This Special Issue will bring together cutting-edge research and reviews on antibody-based strategies that reflect the convergence of immunotechnology and genomics, bridging basic science and clinical applications.

Topics of interest:

• Genomics-driven discovery of therapeutic antibodies and biomarkers
• CRISPR/Cas system delivery via antibody formats
• Antibody development platforms (e.g., phage/yeast/mammalian display, single B cell sequencing)
• Integration of antibody profiling with omics data for patient stratification
• Applications of monoclonal and bispecific antibodies in precision oncology
• Microbial genomics and antibody-based neutralization strategies
• Antibody-drug conjugates (ADCs) targeting genomically-defined tumor antigens
• Bioinformatics and AI in antibody design and epitope prediction
• Nanobody and scFv applications in diagnostics and targeted delivery
• Regulatory and ethical issues in antibody-based personalized therapies

Target Audience

This Special Issue will benefit from a strong professional network across the fields of antibody engineering, genomic medicine, and translational research.

Benefits of submitting by the deadline

• No article processing charges
• Complimentary language editing

For further details, please contact the editorial office at: info@scifiniti.com

Spatial Omics in Cancer: Decoding Heterogeneity, Microenvironment Crosstalk, and Therapeutic Implications

A special issue of GenoMed Connect (ISSN 3006-9033).

Special Issue Editors

Dr. Gao Zhang Lead Guest Editor The University of Hong Kong, Pokfulam, Hong Kong

Overview and Rationale

Background
Spatial omics technologies are transforming biomedical research by profiling molecular signatures within their native tissue context. This approach overcomes the limitations of traditional methods by simultaneously resolving cell types, functional states, and their spatial interactions. By illuminating tumor-stroma crosstalk and resistance niches, spatial omics provides unprecedented insights into the tumor microenvironment. This paradigm shift from what is expressed to where and how molecular interactions occur is advancing oncology into an era of spatially-informed precision medicine.

Objectives

1. Showcase innovative applications of spatial omics in decoding tumor heterogeneity and the tumor microenvironment.
2. Elucidate the spatial drivers of intercellular communication, niche formation, and therapy resistance.
3. Foster collaboration between computational biology, bioengineering, and clinical oncology.
4. Explore spatially-guided strategies for personalized treatment and targeted therapies.

Scope

This issue will feature the latest innovations and translational applications of spatial omics in oncology. We invite original research articles, reviews, perspectives, and clinical trial reports. Key topics include, but are not limited to:

1. Technology Development: Advanced spatially resolved technologies and novel computational tools.
2. Biological Discoveries: Insights into tumor clonal evolution, pre-metastatic niche remodeling, and spatial immune architecture.
3. Clinical Translation: Research on spatial biomarkers, pathology subtyping, and spatial endpoints in clinical trials.

We also encourage submissions from other fields, such as neuroscience and developmental biology, that offer cross-disciplinary insights into microenvironmental regulation.

Topics of interest:

• Integrating Spatial Transcriptomics and Proteomics to Decode the Immunosuppressive Niche in Pancreatic Cancer
• Novel Computational Pipeline for Deconvoluting Cellular Neighborhoods from Multiplexed Imaging Data
• Spatial Evolution of Therapy-Resistant Clones Revealed by Single-Cell Multi-omics in Breast Cancer Liver Metastases
• Three-Dimensional Mapping of Immune-Tumor Interactions in Colorectal Cancer Using Spatial ATAC-seq
• A Spatial Biomarker Signature Predicting PD-1 Blockade Response in Melanoma: A Multicenter Validation Study
• Artificial Intelligence-Assisted Spatial Pathology for Guiding Precision Biopsy in Prostate Cancer
• Spatial Metabolomics Reveals Nutrient Competition Zones as Novel Therapeutic Targets in Triple-Negative Breast Cancer
• Machine Learning-Based Integration of Spatial Transcriptomics and Histopathology for Predicting Lymphoma Progression
• Dynamic Remodeling of Tumor-Stroma Spatial Networks During Neoadjuvant Chemotherapy in Gastric Cancer
• Spatial Epigenetic Mapping of the Premetastatic Niche in Colorectal Cancer Liver Metastasis

Benefits of submitting by the deadline

• No article processing charges
• Complimentary language editing

For further details, please contact the editorial office at: info@scifiniti.com